AIPher

Discovers naturally derived drugs from plants and microbes using its in-house AI foundation model PRISM; three oral drug candidates have entered clinical trials

Series D+ · $845M · 2026-09 · Valuation $2.0B

Open AI models and agents for molecular modeling and drug discovery

Seed · $28M · 2026-01

Links leading US academic biobanks into a unified research network producing training-ready multimodal datasets, and trains disease-specific AI foundation models on them that transfer across diseases, for disease detection, biomarker discovery and drug development

Undisclosed · $50M · 2026-08

Novel drugs for CNS psychiatric and neurological disorders, with the NeuChime small-molecule discovery platform and NeuGem AAV gene therapy platform; lead programs include NS-136 (M4 positive allosteric modulator) and NS-041 (KCNQ2/3 activator)

Series B · 2026-09

AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.

Angel · 2026-10

AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials

Series D+ · $210M · 2025-03

AI-native drug discovery: patient-derived disease models and generative AI to design small-molecule cancer/fibrosis therapies

Pre-Seed · $3M · 2026-07

Turns biology AI foundation models into reproducible drug discovery workflows for pharma teams

Seed · $20M · 2026-04

AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies

Series B · $2.7B · 2026-05

Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design

Seed · $14M · 2026-08

Develops AI models for drug discovery

AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery

Series B · $58M · 2026-02